Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMQV3IM)

Drug Name	SAR445088 DMQV3IM

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Immune thrombocytopenia	DISVCBNS	3B64	Phase 2	[1]
Chronic inflammatory demyelinating polyneuropathy	DISNGBLD	8C01.3	Phase 2	[2]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Autoimmune haemolytic anaemia	DIS7MS3M	3A20	Phase 1	[3]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04669600) A Multicenter, Phase 2a, Open-label, Non-randomized Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP). U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT04658472) A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). U.S.National Institutes of Health.
3	ClinicalTrials.gov (NCT04802057) An Open-label, Long-term, Safety and Tolerability Study of SAR445088 in Participants With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088. U.S.National Institutes of Health.